Merck Sharp + Dohme Corp.

Sutthilug Sotthivirat

Majid Mahjour

Feng Li

Sachin Mittal

Decheng Ma

Justin Moser

Bhagwant Rege

Craig A McKelvey

Sarah Geers

Dina Zhang

Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise:

Solid pharmaceutical compositions containing an integrase inhibitor

Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described.

Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

CB-1 receptor modulator formulations

Growing community of inventors

Lansdale, PA, United States of America

Sutthilug Sotthivirat